| Objectives: Injury of the brain tissue after intracerebral hemorrhage, once was noticed as the direct oppression of the hematoma. But recently the researchers believe that unless the space occupying lesion of the hematoma, there're still other mechanisms to lead the injury such as circulatory disorder,metabolic disorder(eg:acid poisoning),vasomotion disorder,BBB damage,cytotoxic effect of the blood breakdown product and so forth.Accordingly, addition to the routine therapy such as lowering the ICP,ajusting BP ect., we also need to do something to cure the circulatory disorder,metabolic disorder,cytotoxic effect of the blood breakdown product ect.Ginkgo biloba extract has been therapeutically used for several decades to increase peripheral and cerebral blood flow as well as for the treatment of dementia. The extract contains multiple compounds such as flavonoids and terpenoids that are thought to contribute to its neuroprotective and vasotropic effects. The mechanism of neuroprotection described include those on cerebral blood flow, neurotransmitter systems, cellular redox state ect. Researches proved that use EGb to treat ICH could profit the hematoma absorption,lessening brain edema and benefit to the recover of the neuro-function, to lower the mortality,aggravation and mutilation.But the recent recearches were all small sample recearch,most of them only mentioned the therapeutic use,and seldom discuse the safety and adverse effect of EGb.Methods: Our research was a retuospective study,the data camefrom the ICH patients in our hospital between Jan. 2002 and Jun. 2006. There're 340 cases who use Egb (basal ganglia ICH 267 cases), and basal ganglia ICH 176 cases which didn't use EGb as control group. All the patients were Han nationality, their age and sex had no statistic diffrence. Stroke was defined according to the National cerebrovascular diseases diagnosis criteria,and all verificated by CT. Admission clinical characteristics (age, sex, nationality, history,etc.) were recorded. The two group all used Mannitol and neuro-noruishment therapy. The EGb group used Egb (10ml or 20ml/day), and the contol group didn't use EGb. Use CSS scale to measure the conscious state,anepia and dyskinesis twice separately at their admittion and discharge. Compare the inprovment rate and standard inprovment rate btween the two group, and minetime the inprovment of the neuro-function. Then compare the mortality and aggravation rate of the two group. Study the adverse function of the two group during the treatment period, than identify the relationship between the adverse function and the EGb.Result: the improvement rate of EGb group (55.9%) was higher than the control group (42.6%) (P<0.05). The aggravation rate of the EGb group was 0.3%, lower than the control group (4.0%), and the mortality of the EGb group was 0.3%, still lower than the control group (P<0.05). In the 340 cases of the EGb group, there're 6 cases which showed adverse function. 2 of them have rash, 1 felt itch surround the bellybutton, 1 felt disorder everywhere, the disorders all disapeired after EGb withdrawal. 1 case felt dysphoria, we thought that the cases which aggravate had no relationship to the use ofEGb.There's no rehaemorrhagia case in the EGb group.Conclusions: EGb to treat ICH could benefit to the recover of the neuro-function, it can lower the mortality,aggravation and mutilation. The main adverse function was allergic response,mostly showed off rash, and it can also showed off itch of skin. Such symptom could disappear when EGb withdrawal. Recent clinical data showed that, use EGb to treat ICH did not raise the risk of rehaemorrhagia, and also the aggravation rate and mortality.
|
PDF Full Text Request